Skip to Navigation Skip to Search Skip to Content
Search All Centers

BTK Inhibitor Update From ASH 2017: What Are the Real-World Results?

Read Transcript Download/Print Transcript

Published on February 19, 2018

How effective are BTK inhibitors for CLL? Do patients tolerate them well in the real-world? Our panel of CLL experts, including Dr. Anthony Mato from the Abramson Cancer Center, and Dr. Jennifer Brown from the Dana-Farber Cancer Institute, joined us at the American Society of Hematology (ASH) 2017 annual meeting to provide an update on the use of BTK inhibitors for CLL treatment. They discuss the treatment’s efficacy, toxicity profile, and the risk for cardiac issues.  Watch now to find out the latest news on BTK inhibitors.

This program is a Patient Empowerment Network program produced by PatientPower. We thank AbbVie, Inc. and Genentech for their support.

Featuring

You might also like

Transcript | BTK Inhibitor Update From ASH 2017: What Are the Real-World Results?

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

You might also like